公开(公告)号：US10377770B2

公开(公告)日：2019-08-13

申请号：US16062680

申请日：2016-12-15

申请人： Novartis AG

发明人： Robert John Aversa ,  Matthew T. Burger ,  Michael Patrick Dillon ,  Thomas A. Dineen, Jr. ,  Rajesh Karki ,  Savithri Ramurthy ,  Vivek Rauniyar ,  Richard Robinson ,  Patrick James Sarver

IPC分类号： C07D487/04 ,  C07D491/04 ,  C07D498/04 ,  A61P35/00 ,  C07D491/044

摘要： The present invention provides compounds of Formula (A): (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent, and methods of using the compositions and combinations to treat conditions including cancers.

公开(公告)号：US10975080B2

公开(公告)日：2021-04-13

申请号：US15736959

申请日：2016-06-15

申请人： NOVARTIS AG

发明人： Jeffrey T. Bagdanoff ,  Zhuoliang Chen ,  Michael Dore ,  Jorge Garcia Fortanet ,  Mitsunori Kato ,  Matthew J. LaMarche ,  Patrick James Sarver ,  Michael Shultz ,  Troy Douglas Smith ,  Sarah Williams

IPC分类号： C07D487/04 ,  C07D519/00 ,  C07D471/04 ,  A61K31/4523 ,  A61P35/00

摘要： The present invention relates to compounds of formula I: in which Y1, Y2, Y3, Y4 R1, R2, R4a, R4b, R5a, R5b, R6a and R6b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.

公开(公告)号：US20190185475A1

公开(公告)日：2019-06-20

申请号：US15736959

申请日：2016-06-15

申请人： NOVARTIS AG

发明人： Jeffrey T. Bagdanoff ,  Zhuoliang Chen ,  Michael Dore ,  Jorge Garcia Fortanet ,  Mitsunori Kato ,  Matthew J. LaMarche ,  Patrick James Sarver ,  Michael Shultz ,  Troy Douglas Smith ,  Sarah Williams

IPC分类号： C07D487/04 ,  A61P35/00 ,  C07D519/00

CPC分类号： C07D487/04 ,  A61P35/00 ,  C07D471/04 ,  C07D519/00

摘要： The present invention relates to compounds of formula I: in which Y1, Y2, Y3, Y4 R1, R2, R4a, R4b, R5a, R5b, R6a and R6b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.

公开(公告)号：US20220089597A1

公开(公告)日：2022-03-24

申请号：US17191082

申请日：2021-03-03

申请人： NOVARTIS AG

发明人： Jeffrey T. Bagdanoff ,  Zhuoliang Chen ,  Michael Dore ,  Jorge Garcia Fortanet ,  Mitsunori Kato ,  Matthew J. LaMarche ,  Patrick James Sarver ,  Michael Shultz ,  Troy Douglas Smith ,  Sarah Williams

IPC分类号： C07D487/04 ,  C07D519/00 ,  C07D471/04 ,  A61K31/4523 ,  A61P35/00

摘要： The present invention relates to compounds of formula I: in which Y1, Y2, Y3, Y4 R1, R2, R4a, R4b, R5a, R5b, R6a and R6b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.

公开(公告)号：US20210309663A1

公开(公告)日：2021-10-07

申请号：US17191139

申请日：2021-03-03

申请人： NOVARTIS AG

发明人： Jeffrey T. Bagdanoff ,  Zhuoliang Chen ,  Michael Dore ,  Jorge Garcia Fortanet ,  Mitsunori Kato ,  Matthew J. LaMarche ,  Patrick James Sarver ,  Michael Shultz ,  Troy Douglas Smith ,  Sarah Williams

IPC分类号： C07D487/04 ,  C07D519/00 ,  C07D471/04 ,  A61K31/4523 ,  A61P35/00

摘要： The present invention relates to compounds of formula I: in which Y1, Y2, Y3, Y4 R1, R2, R4a, R4b, R5a, R5b, R6a and R6b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.

公开(公告)号：US10287266B2

公开(公告)日：2019-05-14

申请号：US15736925

申请日：2016-06-15

申请人： NOVARTIS AG

发明人： Zhuoliang Chen ,  Jorge Garcia Fortanet ,  Andriana Jouk ,  Rajesh Karki ,  Matthew J. LaMarche ,  Gang Liu ,  Mark G. Palermo ,  Lawrence Blas Perez ,  Patrick James Sarver ,  Michael David Shultz ,  Martin Sendzik ,  Bakary-Barry Toure ,  Bing Yu

IPC分类号： C07D401/14 ,  C07D401/04 ,  C07D471/10 ,  C07D491/107 ,  C07D498/10

摘要： The present invention relates to compounds of formula I: in which Y1, Y2, Y3, R1, R2, R4a, R4b, R5a, R5b, R6a and R6b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.